A comprehensive overview of GLP-1 receptor agonists — approved medications, clinical evidence, regulatory status, and safety considerations.
Filed under approved medicines, written for patient-consumer, clinician, pharmacist-compounder, researcher, evidence level A.
Not medically reviewed. Last updated 2026-05-01. Nothing here is medical advice.
GLP-1 (glucagon-like peptide-1) receptor agonists are among the most significant peptide-based drug classes in modern medicine. Originally developed for type 2 diabetes, they have expanded into obesity treatment and are being investigated for cardiovascular, neurological, and other indications.
Several GLP-1 receptor agonists have received FDA approval:
GLP-1 receptor agonists have been studied in large-scale randomized controlled trials involving tens of thousands of participants. Evidence supports their efficacy for glycemic control, weight management, and cardiovascular risk reduction.
The FDA has taken significant action regarding GLP-1 compounding. Due to a resolved drug shortage, the regulatory framework around compounded semaglutide has shifted. Compounding pharmacies face evolving restrictions on preparing copies of commercially available GLP-1 medications.
Common side effects include nausea, vomiting, diarrhea, and constipation. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in rodent studies). Patients should discuss risks and benefits with their healthcare provider.
This article is for educational purposes only and does not constitute medical advice.
More guides: All guides, Safety centre, Peptide library.